Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enanta Pharmaceuticals reports strong Q1 earnings and advances antiviral programs

Enanta Pharmaceuticals delivered solid financial performance in Q1 2023, backed by revenue from AbbVie's MAVYRET sales and a strong cash position for future operations.
The company's focus on advancing their COVID-19 program, RSV therapeutics, and antiviral research programs demonstrates a commitment to addressing critical medical challenges.
While Enanta faces challenges in clinical development and market competition, opportunities in expanding their antiviral portfolio and presenting upcoming data offer avenues for growth.

Enanta Pharmaceuticals excels in COVID-19 treatment pipeline expansion

Enanta Pharmaceuticals showcased positive outcomes from the Phase 2 study of EDP-235 for COVID-19, emphasizing safety and symptom improvement.
The company's diversified pipeline, financial flexibility enhancement, and proactive strategic planning reflect a robust operational framework.
Challenges include demonstrating direct antiviral effects of EDP-235 and addressing regulatory and safety considerations in patient populations.
Opportunities lie in expanding therapeutic reach, capitalizing on market prospects, and addressing evolving healthcare needs in COVID-19 treatment.
Analyst interest in EDP-235's benefits, market opportunities, and patient population considerations underscores investor confidence and strategic relevance.

Enanta Pharmaceuticals reports positive Q3 results and growth opportunities

Enanta Pharmaceuticals showcased progress in RSV and COVID-19 programs with positive Phase I data.
Financially, the company reported revenue of $18.9 million and expects cash reserves to support operations into 2027.
Focus on high-risk patient populations and exploration of partnerships present growth opportunities.

Enanta Pharmaceuticals reports strong Q4 earnings, advances RSV program

Enanta Pharmaceuticals reported solid financial performance in Q4 2023, with a focus on cost reduction and strategic allocation of resources.
The company's RSV program progress and adjustments to prioritize key studies demonstrate a commitment to advancing its pipeline and making informed decisions.
While facing challenges in clinical trial recruitment and navigating the impact of COVID, Enanta remains focused on exploring new therapeutic avenues and leveraging opportunities for growth.
Ongoing discussions with the FDA, progress in key studies, and strategic decision-making underscore Enanta's efforts to drive innovation and address medical needs.

Enanta Pharmaceuticals reports Q1 revenue, progresses in RSV and immunology

Enanta Pharmaceuticals is progressing well in RSV and immunology programs, with a focus on oral treatments for respiratory syncytial virus and chronic spontaneous urticaria.
Financially, the company reported total revenue of $18 million, decreased R&D expenses, and ended the quarter with $337 million in cash and marketable securities.
Challenges include ongoing financial losses, the need for successful Phase 2 studies, and developing a best-in-disease oral KIT inhibitor.
Opportunities lie in market demand for oral treatments, entering markets with high unmet medical needs, and developing compounds with selectivity against KIT kinase.

Enanta Pharmaceuticals reports solid Q2 earnings amidst pipeline advancements

Enanta Pharmaceuticals is strategically positioned with a focus on virology and immunology, strong financial stability, and promising pipeline candidates like zelicapavir and EDP-323.
While facing challenges such as patent litigation, the company's emphasis on innovation and potential expansion into new indications presents exciting growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Investor Conferences in September.

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. A live webcast of the even.

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY. A live webcast of the ev.

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode.

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago.

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. “At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver mu.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals' Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta's new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its commo.

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. “I'm pleased to welcome Matt to Enanta. The breadth of his leg.

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, includ.

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain. The poster presentation includes primary and post-hoc a.

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL. A live webcast of th.

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023. “In 2024, Enanta began a year which will be marked by execution and value creation across the company. We are preparing for multiple catalysts across our pipeline in 2024, starting with RSV, where we anticipate reporting to.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 11:20 a.m. ET. A live webca.

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company's bu.

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology, today announced that Jay R. Luly, Ph.D., Enanta's President and Chief Executive Officer, will provide an update across its pipeline and plans for 2024 during Enanta's presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. P.

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT in San Francisco, CA. A live webcast of the event will be accessible by visiting the “Event.

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Hippo Holdings

China Lodging Group

KNOT Offshore Partners

OneConnect Financial Tech Co Ltd ADR

Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.

News for Enanta Pharmaceuticals Stock (ENTA)